Rationale for anti-CD137 cancer immunotherapy

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 112-119

  Makkouk, Amani ^a   Chester, Cariad ^a   Kohrt, Holbrook E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bispecific antibodies; Cancer immunotherapy; CAR; CD137; Cytotoxic T cells; Monoclonal antibodies; Natural killer cells; Tumour microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD137 ANTIGEN;

ADAPTIVE IMMUNITY; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84952932933     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.09.026     Document Type: Review

References (70)

1. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 480 2011 480 489
2. A. Makkouk, and G.J. Weiner Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge Cancer Res 75 2015 5 10
3. A. Shanker, and F.M. Marincola Cooperativity of adaptive and innate immunity: implications for cancer therapy Cancer Immunol Immunother 60 2011 1061 1074
4. T.F. Gajewski, H. Schreiber, and Y.X. Fu Innate and adaptive immune cells in the tumor microenvironment Nat Immunol 14 2013 1014 1022
5. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nature Rev Cancer 12 2012 252 264
6. S.L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
7. L. Chen, and D.B. Flies Molecular mechanisms of T cell co-stimulation and co-inhibition Nat Rev Immunol 13 2013 227 242
8. B.S. Kwon, and S.M. Weissman cDNA sequences of two inducible T-cell genes Proc Natl Acad Sci U S A 86 1989 1963 1967
9. I. Melero, W.W. Shuford, S.A. Newby, A. Aruffo, J.A. Ledbetter, K.E. Hellström, and et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors Nat Med 3 1997 682 685
10. I. Melero, J.V. Johnston, W.W. Shufford, R.S. Mittler, and L. Chen NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies Cell Immunol 190 1998 167 172
11. M.S. Sabel, T.F. Conway, F.A. Chen, and R.B. Bankert Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice J Immunother 23 2000 362 368
12. M. Croft, C.A. Benedict, and C.F. Ware Clinical targeting of the TNF and TNFR superfamilies Nat Rev Drug Discov 12 2013 147 168
13. T.H. Watts TNF/TNFR family members in costimulation of T cell responses Annu Rev Immunol 23 2005 23 68
14. M. Croft The TNF family in T cell differentiation and function-unanswered questions and future directions Semin Immunol 26 2014 183 190
15. M. Wolfl, J. Kuball, W.Y. Ho, H. Nguyen, T.J. Manley, M. Bleakley, and et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities Blood 110 2007 201 210
16. S. Schmied, E. Gostick, D.A. Price, H. Abken, M. Assenmacher, and A. Richter Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation Immunology 145 2015 558 569
17. D.S. Vinay, and B.S. Kwon Immunotherapy of cancer with 4-1BB Mol Cancer Ther 11 2012 1062 1070
18. D.H. Kim, W.S. Chang, Y.S. Lee, K.A. Lee, Y.K. Kim, B.S. Kwon, and et al. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation J Immunol 180 2008 2062 2068
19. T. So, S.W. Lee, and M. Croft Immune regulation and control of regulatory T cells by OX40 and 4-1BB Cytokine Growth Factor Rev 19 2008 253 262
20. C. Wang, G.H. Lin, A.J. McPherson, and T.H. Watts Immune regulation by 4-1BB and 4-1BBL: complexities and challenges Immunol Rev 229 2009 192 215
21. L.M. Snell, G.H. Lin, A.J. McPherson, T.J. Moraes, and T.H. Watts T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy Immunol Rev 244 2011 197 217
22. B.K. Choi, J.S. Bae, E.M. Choi, W.J. Kang, S. Sakaguchi, D.S. Vinay, and et al. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells J Leukoc Biol 75 2004 785 791
23. G. Zheng, B. Wang, and A. Chen The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells J Immunol 173 2004 2428 2434
24. K.G. Elpek, E.S. Yolcu, D.D. Franke, C. Lacelle, R.H. Schabowsky, and H. Shirwan Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling J Immunol 179 2007 7295 7304
25. S.J. Robertson, R.J. Messer, A.B. Carmody, R.S. Mittler, C. Burlak, and K.J. Hasenkrug CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells J Immunol 180 2008 5267 5274
26. M.A. Curran, T.L. Geiger, W. Montalvo, M. Kim, S.L. Reiner, A. Al-Shamkhani, and et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of eomesodermin J Exp Med 210 2013 743 755
27. Y.H. Kim, B.K. Choi, S.M. Shin, C.H. Kim, H.S. Oh, S.H. Park, and et al. 4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells J Immunol 187 2011 1120 1128
28. R.A. Wilcox, K. Tamada, S.E. Strome, and L. Chen Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity J Immunol 169 2002 4230 4236
29. H.E. Kohrt, R. Houot, M.J. Goldstein, K. Weiskopf, A.A. Alizadeh, J. Brody, and et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies Blood 117 2011 2423 2432
30. H.E. Kohrt, R. Houot, K. Weiskopf, M.J. Goldstein, F. Scheeren, D. Czerwinski, and et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer J Clin Invest 122 2012 1066 1075
31. H.E. Kohrt, A.D. Colevas, R. Houot, K. Weiskopf, M.J. Goldstein, P. Lund, and et al. Targeting CD137 enhances the efficacy of cetuximab J Clin Invest 124 2014 2668 2682
32. Y. Kuang, X. Weng, X. Liu, H. Zhu, Z. Chen, and H. Chen Effects of 4-1BB signaling on the biological function of murine dendritic cells Oncol Lett 3 2012 477 481
33. Q. Ye, D.G. Song, M. Poussin, T. Yamamoto, A. Best, C. Li, and et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor Clin Cancer Res 20 2014 44 55
34. A. Palazón, A. Teijeira, I. Martínez-Forero, S. Hervás-Stubbs, C. Roncal, I. Peñuelas, and et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes Cancer Res 71 2011 801 811
35. J.A. Hernandez-Chacon, Y. Li, R.C. Wu, C. Bernatchez, Y. Wang, J.S. Weber, and et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function J Immunother 34 2011 236 250
36. R.A. Wilcox, D.B. Flies, H. Wang, K. Tamada, A.J. Johnson, L.R. Pease, and et al. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy Cancer Res 62 2002 4413 4418
37. J.A. Kim, B.J. Averbook, K. Chambers, K. Rothchild, J. Kjaergaard, R. Papay, and et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation Cancer Res 61 2001 2031 2037
38. R.E. Miller, J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak, and et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner J Immunol 169 2002 1792 1800
39. R.A. Wilcox, D.B. Flies, G. Zhu, A.J. Johnson, K. Tamada, A.I. Chapoval, and et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors J Clin Invest 109 2002 651 659
40. R. Houot, M.J. Goldstein, H.E. Kohrt, J.H. Myklebust, A.A. Alizadeh, J.T. Lin, and et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion Blood 114 2009 3431 3438
41. A. Morales-Kastresana, E. Catalán, S. Hervás-Stubbs, A. Palazón, A. Azpilikueta, E. Bolaños, and et al. Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb J Immunother Cancer 1 2013 3
42. O. Murillo, J. Dubrot, A. Palazón, A. Arina, A. Azpilikueta, C. Alfaro, and et al. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb Eur J Immunol 39 2009 2424 2436
43. A.M. Krieg Development of TLR9 agonists for cancer therapy J Clin Invest 117 2007 1184 1194
44. J.A. Westwood, N.M. Haynes, J. Sharkey, N. McLaughlin, H.J. Pegram, R.A. Schwendener, and et al. Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice Clin Cancer Res 15 2009 7624 7633
45. A. Gros, P.F. Robbins, X. Yao, Y.F. Li, S. Turcotte, E. Tran, and et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors J Clin Invest 124 2014 2246 2259
46. M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, D.E. White, and et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 2009 1537 1544
47. I. Verbrugge, J. Hagekyriakou, L.L. Sharp, M. Galli, A. West, N.M. McLaughlin, and et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies Cancer Res 72 2012 3163 3174
48. M.A. Curran, M. Kim, W. Montalvo, A. Al-Shamkhani, and J.P. Allison Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production PLoS One 6 2011 e19499
49. Á. Teijeira, A. Palazón, S. Garasa, D. Marré, C. Aubá, A. Rogel, and et al. CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells FASEB J 26 2012 3380 3392
50. A. Palazón, I. Martínez-Forero, A. Teijeira, A. Morales-Kastresana, C. Alfaro, M.F. Sanmamed, and et al. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy Cancer Discov 2 2012 608 623
51. A.A. Alizadeh, A.J. Gentles, A.J. Alencar, C.L. Liu, H.E. Kohrt, R. Houot, and et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment Blood 118 2011 1350 1358
52. M.W. Anderson, S. Zhao, A.G. Freud, D.K. Czerwinski, H. Kohrt, A.A. Alizadeh, and et al. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications Am J Pathol 181 2012 795 803
53. J.M. Taube, R.A. Anders, G.D. Young, H. Xu, R. Sharma, T.L. McMiller, and et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
54. M. Sznol, and L. Chen Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer Clin Cancer Res 19 2013 1021 1034
55. M.W. Teng, S.F. Ngiow, A. Ribas, and M.J. Smyth Classifying Cancers Based on T-cell infiltration and PD-L1 Cancer Res 75 2015 2139 2145
56. M. Sznol, F.S. Hodi, K. Margolin, D.F. McDermott, M.S. Ernstoff, J.M. Kirkwood, and et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) J Clin Oncol (Meeting Abstracts) 26 2008 (Suppl. 15):3007
57. N.H. Segal, A.K. Gopal, S. Bhatia, H.E. Kohrt, R. Levy, M.J. Pishvaian, and et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer J Clin Oncol (Meeting Abstracts) 32 2014 (Suppl. 15):3007
58. J. Dubrot, F. Milheiro, C. Alfaro, A. Palazón, I. Martinez-Forero, J.L. Perez-Gracia, and et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ Cancer Immunol Immunother 59 2010 1223 1233
59. J.S. Weber Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist Am Soc Clin Oncol Educ Book 2012 174 177
60. M. Sadelain, I. Rivière, and R. Brentjens Targeting tumours with genetically enhanced T lymphocytes Nature Rev Cancer 3 2003 35 45
61. M.H. Kershaw, J.A. Westwood, C.Y. Slaney, and P.K. Darcy Clinical application of genetically modified T cells in cancer therapy Clin Trans Immunol 3 2014 e16
62. D.-G. Song, Q. Ye, C. Carpenito, M. Poussin, L.-P. Wang, C. Ji, and et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) Cancer Res 71 2011 4617 4627
63. C. Imai, K. Mihara, M. Andreansky, I.C. Nicholson, C.-H. Pui, T.L. Geiger, and et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 18 2004 676 684
64. K. Schönfeld, C. Sahm, C. Zhang, S. Naundorf, C. Brendel, M. Odendahl, and et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor Mol Ther 23 2015 330 338
65. M.C. Milone, J.D. Fish, C. Carpenito, R.G. Carroll, G.K. Binder, D. Teachey, and et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 17 2009 1453 1464
66. S.J. Schuster, J. Svoboda, S. Nasta, D.L. Porter, A. Mato, G.D. Shah, and et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas J Clin Oncol (Meeting Abstracts) 2015 (suppl; abstr 8516)
67. N. Bumma, N. Papadantonakis, and A.S. Advani Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia Future Oncol 11 2015 1729 1739
68. C. Arndt, A. Feldmann, M. von Bonin, M. Cartellieri, E.-M. Ewen, S. Koristka, and et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system Leukemia 28 2014 59 69
69. F. Pastor, D. Kolonias, J.O. McNamara, and E. Gilboa Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers Mol Ther 19 2011 1878 1886
70. Pieris Pharmaceuticals Pieris pharmaceuticals to present data on novel anti-cd137 and her2 bispecific immuno-oncology program at ubs global healthcare conference 2015 Press Release